EUVIMEDEUVIMED entdecken
Crossref

Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features

Austin T Armstrong iD, Lisa M Velez-Velez, Matt C Simpson, Sean T Massa iD

Otolaryngology–Head and Neck Surgery · 2023

DOI: 10.1002/ohn.252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2023. Verfasst von Austin T Armstrong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Extranodal Extension, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Determine trends and survival implications of adjuvant systemic therapy use for lower risk head and neck cancer. Study Design Retrospective cohort study.

Setting

US National Cancer Database, 2010 to 2019.

Methods

Patients with mucosal head and neck squamous cell carcinoma treated with surgery and postoperative radiation therapy were identified. Adjuvant systemic therapy trends in those with and without extranodal extension or positive margins were assessed as annual percent change by JoinPoint analysis. Factors associated with adjuvant systemic therapy and overall survival were assessed with multivariable models and cox proportional hazard models, respectively.

Results

From 2010 to 2019, approximately one‐third of head and neck cancer patients without extranodal extension or positive margins received adjuvant systemic therapy. This rate decreased throughout the study period, with the highest annual percent change from 2016 to 2019 (12.21%; 95% confidence interval: 3.73%‐19.95%). Younger age, male sex, Hispanic ethnicity, community program setting, advanced stage, and lymphovascular invasion increased the odds a patient would receive adjuvant systemic therapy. Adjuvant systemic therapy was associated with inferior overall survival when used in those without extranodal extension or positive margins after controlling for covariates.

Conclusion

Though decreasing, adjuvant systemic therapy use is still common in the absence of extranodal extension and positive margins, and a variety of patient, provider, and oncologic factors may influence its use. The inferior overall survival after adjuvant systemic therapy in the absence of high‐risk features suggests any oncologic benefit may not outweigh the costs and morbidity of the therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extranodal ExtensionHead and Neck NeoplasmsHumansMaleRetrospective StudiesChemoradiotherapy, AdjuvantRisk FactorsRadiotherapy, AdjuvantNeoplasm Staging

Stichwörter der Autor:innen

adjuvant therapyhead and neck cancersurvivalsystemic therapy

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, USA.

ORCID-Profile: Austin T Armstrong, Sean T Massa

Zitieren

APA

Armstrong, A. T., Velez-Velez, L. M., Simpson, M. C., & Massa, S. T. (2023). Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.252

Vancouver

Armstrong AT, Velez-Velez LM, Simpson MC, Massa ST. Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.252

BibTeX
@article{Armstrong2023,
  author = {Armstrong, Austin T and Velez-Velez, Lisa M and Simpson, Matt C and Massa, Sean T},
  title = {Trends and Implications of Adjuvant Systemic Therapy for Head and Neck Cancer Without High‐Risk Features},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2023},
  doi = {10.1002/ohn.252}
}
Kostenlos starten →